Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN versus VIGADRONE.
GABAPENTIN vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin is a structural analog of GABA but does not bind to GABA receptors. It binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
Initial dose: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate as needed up to 1800-3600 mg/day in three divided doses. Maximum single dose: 1200 mg. Dose adjustments for renal impairment should be made based on creatinine clearance.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
Clinical Note
moderateGabapentin + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate."
Clinical Note
moderateGabapentin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Gabapentin."
Clinical Note
moderateGabapentin + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Gabapentin."
Clinical Note
moderateGabapentin + Clemastine
5-7 hours (normal renal function); prolonged to 50-140 hours in end-stage renal disease; half-life independent of dose due to linear kinetics.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Renal: 76-81% unchanged in urine; biliary/fecal: <5% as metabolites; remainder (10-20%) as minor metabolites via urine.
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine."